Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Patients with Schizophrenia
100%
Prefrontal Cortex
100%
DARPP-32
100%
Schizophrenic Patients
83%
Prefrontal Dysfunction
50%
Control Subjects
33%
Alzheimer's Disease
33%
CaMKII
33%
Glutamate
33%
Synapsin
33%
Schizophrenia
16%
Potent Inhibitor
16%
Dorsolateral Prefrontal Cortex (DLPFC)
16%
Dopamine
16%
Protein Phosphatase
16%
Phosphoprotein
16%
Synaptic
16%
Illness
16%
2 Receptor
16%
Dopamine Receptor
16%
Immunoblotting
16%
N-methyl-D-aspartate
16%
Postmortem Samples
16%
Glutamate Receptors
16%
Selective Reduction
16%
Ion Channels
16%
Between-subject
16%
Autolysis
16%
Confounding Influences
16%
Neurotransmitter Dopamine
16%
Pathophysiological Changes
16%
Neuroscience
Prefrontal Cortex
100%
Phosphoprotein DARPP 32
100%
Typical Antipsychotic
50%
Alzheimer's Disease
33%
Synapsin I
33%
Glutamic Acid
33%
Calcium Calmodulin Dependent Protein Kinase II
33%
Receptor
33%
Aspartic Acid
16%
Neurotransmitter
16%
Dorsolateral Prefrontal Cortex
16%
Phosphoprotein
16%
Dopamine Receptor
16%
Phosphoprotein Phosphatase 1
16%
Glutamate Receptor
16%
Ion Channel
16%
Immunoblotting
16%
Antipsychotic
16%